These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34359741)

  • 1. Expression of HLA-DR in Cytotoxic T Lymphocytes: A Validated Predictive Biomarker and a Potential Therapeutic Strategy in Breast Cancer.
    Saraiva DP; Azeredo-Lopes S; Antunes A; Salvador R; Borralho P; Assis B; Pereira IL; Seabra Z; Negreiros I; Jacinto A; Braga S; Cabral MG
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy.
    Saraiva DP; Jacinto A; Borralho P; Braga S; Cabral MG
    Front Immunol; 2018; 9():2605. PubMed ID: 30555458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy.
    Osuna-Gómez R; Arqueros C; Galano C; Mulet M; Zamora C; Barnadas A; Vidal S
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
    Yao L; Jia G; Lu L; Ma W
    Curr Oncol; 2022 Jul; 29(7):4902-4913. PubMed ID: 35877249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients.
    König L; Kasimir-Bauer S; Hoffmann O; Bittner AK; Wagner B; Manvailer LF; Schramm S; Bankfalvi A; Giebel B; Kimmig R; Horn PA; Rebmann V
    Hum Immunol; 2016 Sep; 77(9):791-9. PubMed ID: 26796737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease.
    Norose K; Yano A
    Br J Ophthalmol; 1996 Nov; 80(11):1002-8. PubMed ID: 8976730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
    Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
    Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide].
    Liu JW; Lu X; Yang ZM; Deng LJ; Yang L
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):840-846. PubMed ID: 29045966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Gu X; Xue JQ; Han SJ; Qian SY; Zhang WH
    Cancer Biomark; 2016; 16(3):395-403. PubMed ID: 27062696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice.
    Savage P; Cowburn P; Clayton A; Man S; Lawson T; Ogg G; Lemoine N; McMichael A; Epenetos A
    Int J Cancer; 2002 Apr; 98(4):561-6. PubMed ID: 11920616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients.
    Skarping I; Förnvik D; Heide-Jørgensen U; Sartor H; Hall P; Zackrisson S; Borgquist S
    Cancer Causes Control; 2021 Mar; 32(3):251-260. PubMed ID: 33377172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-J, a Non-Pseudogene as a New Prognostic Marker for Therapy Response and Survival in Breast Cancer.
    Würfel FM; Wirtz RM; Winterhalter C; Taffurelli M; Santini D; Mandrioli A; Veltrup E; Rübner M; Fasching PA; Würfel W; Zamagni C
    Geburtshilfe Frauenheilkd; 2020 Nov; 80(11):1123-1133. PubMed ID: 33173240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+HLA-DR+ T cells are increased in patients with severe aplastic anemia.
    Xing L; Liu C; Fu R; Wang H; Wang J; Liu X; Feng L; Li L; Liu H; Wang H; Zhang T; Shao Z
    Mol Med Rep; 2014 Sep; 10(3):1252-8. PubMed ID: 24969051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
    D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
    Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lymphocyte activation markers in patients with ovarian cancer].
    Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
    Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells.
    Sumransub N; Jirapongwattana N; Jamjuntra P; Thongchot S; Chieochansin T; Yenchitsomanus PT; Thuwajit P; Warnnissorn M; O-Charoenrat P; Thuwajit C
    Oncol Lett; 2020 Mar; 19(3):2422-2430. PubMed ID: 32194742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
    Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
    Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICG fluorescence imaging as a new tool for optimization of pathological evaluation in breast cancer tumors after neoadjuvant chemotherapy.
    Veys I; Pop CF; Barbieux R; Moreau M; Noterman D; De Neubourg F; Nogaret JM; Liberale G; Larsimont D; Bourgeois P
    PLoS One; 2018; 13(5):e0197857. PubMed ID: 29799849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.